NUVL vs. KDNY, PRAX, IGMS, OCGN, VTYX, ALNY, TEVA, GMAB, RPRX, and BMRN
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Chinook Therapeutics (KDNY), Praxis Precision Medicines (PRAX), IGM Biosciences (IGMS), Ocugen (OCGN), Ventyx Biosciences (VTYX), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN).
Nuvalent (NASDAQ:NUVL) and Chinook Therapeutics (NASDAQ:KDNY) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment.
97.3% of Nuvalent shares are held by institutional investors. Comparatively, 95.2% of Chinook Therapeutics shares are held by institutional investors. 12.5% of Nuvalent shares are held by insiders. Comparatively, 16.8% of Chinook Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Nuvalent presently has a consensus price target of $90.78, indicating a potential upside of 14.65%. Chinook Therapeutics has a consensus price target of $41.00, indicating a potential upside of 1.51%. Given Nuvalent's stronger consensus rating and higher probable upside, equities analysts plainly believe Nuvalent is more favorable than Chinook Therapeutics.
Nuvalent has higher earnings, but lower revenue than Chinook Therapeutics. Nuvalent is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nuvalent has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Chinook Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.
Chinook Therapeutics received 2 more outperform votes than Nuvalent when rated by MarketBeat users. However, 71.43% of users gave Nuvalent an outperform vote while only 50.00% of users gave Chinook Therapeutics an outperform vote.
Nuvalent has a net margin of 0.00% compared to Chinook Therapeutics' net margin of -4,199.93%. Nuvalent's return on equity of -26.54% beat Chinook Therapeutics' return on equity.
In the previous week, Nuvalent had 6 more articles in the media than Chinook Therapeutics. MarketBeat recorded 6 mentions for Nuvalent and 0 mentions for Chinook Therapeutics. Nuvalent's average media sentiment score of 1.04 beat Chinook Therapeutics' score of 0.67 indicating that Nuvalent is being referred to more favorably in the media.
Summary
Nuvalent beats Chinook Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvalent Competitors List
Related Companies and Tools
